Akari Therapeutics announced a virtual investor segment discussing its spliceosome modulator PH1 and ongoing cancer research efforts.
Quiver AI Summary
Akari Therapeutics, an oncology biotechnology company focused on developing innovative antibody drug conjugates (ADCs) for cancer treatment, announced that its President and CEO, Abizer Gaslightwala, participated in a Virtual Investor segment discussing the novel spliceosome modulator payload, PH1. This payload is designed to disrupt RNA splicing in cancer cells, differentiating itself from traditional ADC payloads. Akari's lead candidate, AKTX-101, targets the Trop2 receptor and has shown promising preclinical results by inducing cancer cell death while enhancing immune responses. The company is actively generating data to support its novel therapies and exploring additional undisclosed targets using the PH1 payload, with hopes of advancing its product candidates through to clinical trials.
Potential Positives
- Akari Therapeutics announced significant progress in developing its novel spliceosome modulator payload, PH1, which has shown preclinical efficacy in inducing cancer cell death.
- The company's lead candidate, AKTX-101, demonstrated significant activity and prolonged survival in preclinical studies, indicating strong potential as a treatment option.
- AKTX-101 has the potential for synergies with checkpoint inhibitors, enhancing its therapeutic application and effectiveness against cancer.
- Increased visibility through participation in a virtual investor segment may attract investor interest and strengthen market confidence in Akari's innovative oncology solutions.
Potential Negatives
- The press release heavily relies on forward-looking statements, which may indicate a lack of certainty about the company's future performance and the successful development of its product candidates.
- The mention of numerous potential risks and uncertainties might raise concerns among investors regarding the company's ability to achieve its goals and attract future investments.
- There is no disclosure of specific data supporting the claims about the effectiveness and safety of its lead candidate, AKTX-101, which could lead to skepticism about its viability.
FAQ
What recent announcement did Akari Therapeutics make?
Akari Therapeutics announced participation in a Virtual Investor segment featuring CEO Abizer Gaslightwala discussing their novel spliceosome modulator payload, PH1.
What is PH1 in Akari Therapeutics' research?
PH1 is a novel spliceosome modulator designed to disrupt RNA splicing in cancer cells, enhancing anti-tumor activity.
How does AKTX-101 work in cancer treatment?
AKTX-101 targets the Trop2 receptor on cancer cells, delivering the PH1 payload directly to the tumor, showing significant preclinical activity.
What are the benefits of using PH1 compared to traditional ADC payloads?
PH1 differentiates itself by inducing cancer cell death and activating immune responses, unlike traditional Topoisomerase1 or tubulin inhibitors.
Where can I find more information about Akari Therapeutics?
More information about Akari Therapeutics is available on their website www.akaritx.com and their profiles on X and LinkedIn.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$AKTX Insider Trading Activity
$AKTX insiders have traded $AKTX stock on the open market 4 times in the past 6 months. Of those trades, 4 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $AKTX stock by insiders over the last 6 months:
- ABIZER GASLIGHTWALA (President & CEO) has made 4 purchases buying 31,146 shares for an estimated $37,119 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$AKTX Hedge Fund Activity
We have seen 1 institutional investors add shares of $AKTX stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- OMNIA FAMILY WEALTH, LLC removed 24,938 shares (-28.5%) from their portfolio in Q2 2025, for an estimated $29,174
- CATALINA CAPITAL GROUP, LLC removed 13,105 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $16,250
- RENAISSANCE TECHNOLOGIES LLC removed 5,081 shares (-21.7%) from their portfolio in Q1 2025, for an estimated $6,300
- UBS GROUP AG removed 194 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $240
- ROYAL BANK OF CANADA added 100 shares (+inf%) to their portfolio in Q1 2025, for an estimated $124
- SBI SECURITIES CO., LTD. removed 5 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $6
- MORGAN STANLEY added 0 shares (+0.0%) to their portfolio in Q1 2025, for an estimated $0
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$AKTX Analyst Ratings
Wall Street analysts have issued reports on $AKTX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Maxim Group issued a "Buy" rating on 07/18/2025
To track analyst ratings and price targets for $AKTX, check out Quiver Quantitative's $AKTX forecast page.
Full Release
Watch the “What This Means” video here
BOSTON and LONDON, July 29, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel immuno-oncology payload antibody drug conjugates (ADCs) for the treatment of cancer, today announced that Abizer Gaslightwala, President and CEO of Akari Therapeutics participated in a Virtual Investor "What This Means" segment .
As part of the segment, Mr. Gaslightwala discussed its novel spliceosome modulator payload, PH1, and the Company’s ongoing efforts to build on key data for its spliceosome modulator payload with further research ongoing on how the payload can also disrupt key drivers responsible for cancer cell growth.
The Virtual Investor "What This Means" segment featuring Akari is now available here .
About Akari Therapeutics
Akari Therapeutics is an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs). The Company has developed its first novel payload, PH1, a spliceosome modulator designed to disrupt RNA splicing within cells. PH1 is highly differentiated in its mechanism of action against cancer cells from current ADC payloads that use Topoisomerase1 inhibitors or tubulin inhibitors. This splicing modulator has been shown in preclinical animal models to induce cancer cell death while activating immune cells to drive robust and durable activity. Using this novel payload, Akari has the ability to generate multiple ADC molecules based on the desired application to a range of cancer targets of interest. Akari’s lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and delivers its novel PH1 payload directly into the tumor. In preclinical studies, AKTX-101 has shown to have significant activity and prolonged survival, relative to ADCs with traditional payloads. Additionally, AKTX-101 has the potential to be synergistic with checkpoint inhibitors and has demonstrated prolonged survival as both a single agent and in combination with checkpoint inhibitors, as compared to appropriate controls. The Company is generating validating data on its novel payload PH1 to continue advancing its lead asset, as well as other undisclosed targets with this novel payload.
For more information about the Company, please visit www.akaritx.com and connect on X and LinkedIn .
Cautionary Note Regarding Forward-Looking Statements
This press release includes express or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, about the Company that involve risks and uncertainties relating to future events and the future performance of the Company. Actual events or results may differ materially from these forward-looking statements. Words such as “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “future,” “opportunity” “will likely result,” “target,” variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the ability of the Company to advance its product candidates for the treatment of cancer and any other diseases, and ultimately bring therapies to patients; the Company’s targets, plans, objectives or goals for future operations, including those related to its product candidates. These statements are based on the Company’s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific. A number of important factors, including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation: the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of the business; risks related to global as well as local political and economic conditions, including interest rate and currency exchange rate fluctuations; potential delays or failures related to research and/or development of the Company’s programs or product candidates; risks related to any loss of the Company’s patents or other intellectual property rights; any interruptions of the supply chain for raw materials or manufacturing for the Company’s product candidates, including as a result of potential tariffs; the nature, timing, cost and possible success and therapeutic applications of product candidates being developed by the Company and/or its collaborators or licensees; the extent to which the results from the research and development programs conducted by the Company, and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; uncertainty of the utilization, market acceptance, and commercial success of the Company’s product candidates; risks related to competition for the Company’s product candidates; and the Company’s ability to successfully develop or commercialize its product candidates. While the foregoing list of factors presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the SEC, copies of which may be obtained from the SEC’s website at www.sec.gov. The Company assumes no, and hereby disclaims any, obligation to update the forward-looking statements contained in this press release except as required by law.
Investor Relations Contact
JTC Team, LLC
Jenene Thomas
908-824-0775
[email protected]